公开(公告)号：US20130171148A1

公开(公告)日：2013-07-04

申请号：US13700246

申请日：2011-05-27

Applicant: Bart De Goeij ,  Edward Norbert Van Den Brink ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  David Satijn ,  Jan Van De Winkel ,  Paul Parren

Inventor： Bart De Goeij ,  Edward Norbert Van Den Brink ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  David Satijn ,  Jan Van De Winkel ,  Paul Parren

IPC: C07K16/30

CPC classification number: C07K16/30 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  Y02A50/472

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Abstract translation: 公开了与人表皮生长因子受体2（HER2）结合的分离的单克隆抗体以及相关的基于抗体的组合物和分子。 还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。

公开(公告)号：US20120164143A1

公开(公告)日：2012-06-28

申请号：US13337798

申请日：2011-12-27

Applicant: Jessica TEELING ,  Paul PARREN ,  Ole BAADSGAARD ,  Debra HUDSON ,  Jørgen PETERSEN

Inventor： Jessica TEELING ,  Paul PARREN ,  Ole BAADSGAARD ,  Debra HUDSON ,  Jørgen PETERSEN

IPC: A61K39/395 ,  A61N5/06 ,  A61P35/00

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/6869

Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与IL-8结合的分离的人单克隆抗体（例如人IL-8）。 人抗体可以通过进行V-D-J重组和同种型转换，在能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人转基因动物例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物，杂交瘤和产生人抗体的转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20110086366A1

公开(公告)日：2011-04-14

申请号：US12918768

申请日：2009-02-20

Applicant: Aran Frank Labrijn ,  Janine Schuurman ,  Jan Van De Winkel ,  Paul Parren

Inventor： Aran Frank Labrijn ,  Janine Schuurman ,  Jan Van De Winkel ,  Paul Parren

IPC: G01N33/53

CPC classification number: G01N33/6854 ,  G01N2800/50 ,  Y02A50/53

Abstract: The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies.

Abstract translation: 本发明涉及用于评估个体在用能够进行Fab-臂交换的治疗性抗体治疗后发展不良事件的风险的方法和试剂盒，所述方法包括以下步骤：a）从 作为用所述治疗性抗体治疗的候选者的个体，b）测定所述样品是否存在结合已知或怀疑与所述不良事件的致病因子相关联的抗原的循环IgG4抗体，以及c） 步骤b）的测定结果的基础，个体在用治疗性抗体治疗后将发展出所述不良事件的风险，其中所述不良事件发展的风险随着所述循环IgG4抗体水平的增加而增加。

公开(公告)号：US07850962B2

公开(公告)日：2010-12-14

申请号：US11578818

申请日：2005-04-20

Applicant: Jessica Teeling ,  Martin Glennie ,  Paul Parren ,  Arnout F. Gerritsen ,  Sigrid Ruuls ,  Yvo Graus ,  Jan van de Winkel

Inventor： Jessica Teeling ,  Martin Glennie ,  Paul Parren ,  Arnout F. Gerritsen ,  Sigrid Ruuls ,  Yvo Graus ,  Jan van de Winkel

IPC: A61K39/395 ,  A61K39/00 ,  G01N33/53 ,  G01N33/567 ,  G01N33/574 ,  G01N33/00 ,  C07K16/00 ,  C12P21/08 ,  C07K17/00 ,  C07K17/14

CPC classification number: C07K16/2887 ,  A61K39/395 ,  A61K45/06 ,  A61K51/1027 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/734 ,  A61K2300/00

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD20的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 还公开了包含人抗体的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20100291023A1

公开(公告)日：2010-11-18

申请号：US12602434

申请日：2008-05-30

Applicant: Janine Schuurman ,  Tom Vink ,  Jan Van de Winkel ,  Aran Frank Labrijn ,  Paul Parren ,  Frank Beurskens ,  Willem Karel Bleeker ,  Patrick Van Berkel

Inventor： Janine Schuurman ,  Tom Vink ,  Jan Van de Winkel ,  Aran Frank Labrijn ,  Paul Parren ,  Frank Beurskens ,  Willem Karel Bleeker ,  Patrick Van Berkel

IPC: A61K38/20 ,  A61K38/21 ,  A61K39/395 ,  C07K16/44 ,  C07K16/42

CPC classification number: C07K16/283 ,  C07K16/2812 ,  C07K16/2863 ,  C07K16/2887 ,  C07K2317/732

Abstract: The present invention relates to methods for extending the in vivo half-life of an exogenous soluble therapeutic molecule administered to a subject, by administering to said subject the exogenous soluble molecule and a monovalent antibody that binds to the exogenous soluble molecule, as well as method for treating a disease or disorder associated with an insufficient level of an endogenous soluble molecule in a subject, by administering to said subject a monovalent antibody that binds to the endogenous soluble molecule.

Abstract translation: 本发明涉及通过向所述受试者施用外源可溶性分子和结合外源可溶性分子的单价抗体以及方法，用于延长给予受试者的外源可溶性治疗分子的体内半衰期的方法，以及方法 用于治疗与受试者内源性可溶性分子水平不足相关的疾病或病症，通过向所述受试者施用结合内源性可溶性分子的单价抗体。

公开(公告)号：US20100105874A1

公开(公告)日：2010-04-29

申请号：US12593759

申请日：2008-03-28

Applicant: Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschote ,  Paul Parren

Inventor： Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschote ,  Paul Parren

IPC: C07K16/46 ,  C07K16/30 ,  C12Q1/18

CPC classification number: C07K16/468 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2319/00

Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.

Abstract translation: 本发明涉及用于产生双特异性抗体的离体方法，包括以下步骤：a）提供具有第一结合特异性的第一抗体，其中所述第一抗体包含IgG4样CH3区，b）提供第二抗体 具有不同于所述第一结合特异性的第二结合特异性的抗体，其中所述第二抗体包含IgG4样CH3区，c）在还原条件下将所述第一抗体和第二抗体一起温育，所述还原条件允许核心铰链区域中的半胱氨酸经历二硫键 异构化，和d）获得双特异性抗体。 本发明还涉及通过本发明的方法可获得的双特异性抗体。

公开(公告)号：US20090104188A1

公开(公告)日：2009-04-23

申请号：US12207460

申请日：2008-09-09

Applicant: Christian Reiter ,  Francois Habersetzer ,  Anne Fournillier ,  Christian Trepo ,  Claude Desgranges ,  Genevieve Inchauspe

Inventor： Christian Reiter ,  Francois Habersetzer ,  Anne Fournillier ,  Christian Trepo ,  Claude Desgranges ,  Genevieve Inchauspe

IPC: A61K39/395

CPC classification number: G01N33/5767 ,  A61K2039/505 ,  C07K16/109 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/76

Abstract: Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.

Abstract translation: 描述了特异性识别HCV糖蛋白E2的构象依赖性表位并能够中和E2蛋白与敏感细胞的结合的新型抗体。 此外，提供了由上述抗体识别的抗原和表位以及编码所述抗体的多核苷酸。 还提供了包含所述多核苷酸的载体以及转化的宿主细胞及其在所述抗体的产生中的用途。 此外，提供药物和诊断组合物，其包含任何上述抗体，抗原，表位，多核苷酸，载体或细胞。 进一步描述了上述抗体，抗原，多核苷酸和载体在过继性免疫治疗中的用途，优选用于治疗或预防肝移植期间的HCV感染。

公开(公告)号：US20080166802A1

公开(公告)日：2008-07-10

申请号：US11827195

申请日：2007-07-11

Applicant: Jan G.J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jorgen Petersen

Inventor： Jan G.J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jorgen Petersen

IPC: C12N5/00 ,  C07H21/04 ,  C12N15/00

CPC classification number: C07K16/24 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  Y10S514/885

Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US07329405B2

公开(公告)日：2008-02-12

申请号：US10374932

申请日：2003-02-26

Applicant: Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jørgen Petersen

Inventor： Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jørgen Petersen

IPC: A61K39/395 ,  C07K16/24

CPC classification number: C07K16/24 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US07282568B2

公开(公告)日：2007-10-16

申请号：US10738120

申请日：2003-12-16

Applicant: Jessica Teeling ,  Paul Parren ,  Ole Baadsgaard ,  Debra Hudson ,  Jørgen Petersen

Inventor： Jessica Teeling ,  Paul Parren ,  Ole Baadsgaard ,  Debra Hudson ,  Jørgen Petersen

IPC: A61K39/395

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/6869

Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与IL-8结合的分离的人单克隆抗体（例如人IL-8）。 人抗体可以通过进行V-D-J重组和同种型转换，在能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人转基因动物例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物，杂交瘤和产生人抗体的转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。